These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12547652)

  • 1. Effects of HIV protease inhibitor therapy on lipid metabolism.
    Hui DY
    Prog Lipid Res; 2003 Mar; 42(2):81-92. PubMed ID: 12547652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.
    Riddle TM; Fichtenbaum CJ; Hui DY
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):564-70. PubMed ID: 12902799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.
    Riddle TM; Kuhel DG; Woollett LA; Fichtenbaum CJ; Hui DY
    J Biol Chem; 2001 Oct; 276(40):37514-9. PubMed ID: 11546771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.
    Bastard JP; Caron M; Vidal H; Jan V; Auclair M; Vigouroux C; Luboinski J; Laville M; Maachi M; Girard PM; Rozenbaum W; Levan P; Capeau J
    Lancet; 2002 Mar; 359(9311):1026-31. PubMed ID: 11937183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipid disorders in patients with HIV-induced diseases].
    Chanu B; Valensi P
    Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients.
    Jan V; Cervera P; Maachi M; Baudrimont M; Kim M; Vidal H; Girard PM; Levan P; Rozenbaum W; Lombès A; Capeau J; Bastard JP
    Antivir Ther; 2004 Aug; 9(4):555-64. PubMed ID: 15456087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection.
    Graber AL
    Endocr Pract; 2001; 7(6):430-7. PubMed ID: 11747278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.
    Graham NM
    J Acquir Immune Defic Syndr; 2000 Oct; 25 Suppl 1():S4-11. PubMed ID: 11126425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
    Liang JS; Distler O; Cooper DA; Jamil H; Deckelbaum RJ; Ginsberg HN; Sturley SL
    Nat Med; 2001 Dec; 7(12):1327-31. PubMed ID: 11726973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy.
    Bonnet E; Genoux A; Bernard J; Fauvel J; Massip P; Perret B
    Clin Chem Lab Med; 2007; 45(7):815-21. PubMed ID: 17617020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy.
    Kannisto K; Sutinen J; Korsheninnikova E; Fisher RM; Ehrenborg E; Gertow K; Virkamäki A; Nyman T; Vidal H; Hamsten A; Yki-Järvinen H
    AIDS; 2003 Aug; 17(12):1753-62. PubMed ID: 12891061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic complications associated with HIV protease inhibitor therapy.
    Nolan D
    Drugs; 2003; 63(23):2555-74. PubMed ID: 14636077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
    Carr A; Samaras K; Chisholm DJ; Cooper DA
    Lancet; 1998 Jun; 351(9119):1881-3. PubMed ID: 9652687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia and inhibitors of HIV protease.
    Distler O; Cooper DA; Deckelbaum RJ; Sturley SL
    Curr Opin Clin Nutr Metab Care; 2001 Mar; 4(2):99-103. PubMed ID: 11224652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sterol regulatory element-binding proteins and lipid metabolism].
    Tang T; Li Y
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):29-34. PubMed ID: 15881340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.
    Noor MA
    Curr HIV/AIDS Rep; 2007 Aug; 4(3):126-34. PubMed ID: 17883998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance in HIV-related lipodystrophy.
    Mikhail N
    Curr Hypertens Rep; 2003 Apr; 5(2):117-21. PubMed ID: 12642010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.